New Phase III data showed that in patients with multiple lipid problems, Abbott's investigational TriLipix(TM) (ABT-335) combined with AstraZeneca's CRESTOR(R) (rosuvastatin calcium) led to greater
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
The U.S. Food and Drug Administration (FDA) has approved Abbott's TRILIPIX(TM) (fenofibric acid) delayed-release capsules for use along with diet to help lower triglycerides and LDL cholesterol, and
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
AstraZeneca and Abbott have entered into an agreement for AstraZeneca to co-promote Abbott's TRILIPIX, a medication for use alone or in combination with a statin to treat certain lipid disorders. Un
read more » Discuss Add this link to...Bury Add to:
| Bookmarks